Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study

Faldaprevir (BI 201335) is a selective NS3/4A protease inhibitor under development for the treatment of chronic hepatitis C virus (HCV) infection. NS3/4A genotyping and NS3 protease phenotyping analyses were performed to monitor the emergence of resistance in patients with HCV genotype 1 infection r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Berger, Kristi L., Lagacé, Lisette, Triki, Ibtissem, Cartier, Mireille, Marquis, Martin, Lawetz, Carol, Bethell, Richard, Scherer, Joseph, Kukolj, George
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2013
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3811435/
https://ncbi.nlm.nih.gov/pubmed/23877706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00822-13
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados